Dupilumab Improves Esophageal Distensibility in Eosinophilic Esophagitis

(MedPage Today) — The monoclonal antibody dupilumab (Dupixent) led to significant improvements in esophageal distensibility among patients with eosinophilic esophagitis, the randomized REMODEL trial showed.
At 24 weeks, patients taking dupilumab…